Activating JAK-mutations confer resistance to FLT3 kinase inhibitors in FLT3-ITD positive AML in vitro and in vivo

[1]  K. Goldberg,et al.  FDA Approval Summary: Gilteritinib for Relapsed or Refractory Acute Myeloid Leukemia with a FLT3 Mutation , 2021, Clinical Cancer Research.

[2]  M. Deininger,et al.  Dasatinib overcomes stroma-based resistance to the FLT3 inhibitor quizartinib using multiple mechanisms , 2020, Leukemia.

[3]  R. Larson,et al.  Gilteritinib or Chemotherapy for Relapsed or Refractory FLT3-Mutated AML. , 2019, The New England journal of medicine.

[4]  S. Asthana,et al.  Clonal selection with Ras pathway activation mediates secondary clinical resistance to selective FLT3 inhibition in acute myeloid leukemia. , 2019, Cancer discovery.

[5]  M. Carroll,et al.  Hematopoietic cytokines mediate resistance to targeted therapy in FLT3-ITD acute myeloid leukemia. , 2019, Blood advances.

[6]  R. Collins,et al.  Clinical resistance to crenolanib in acute myeloid leukemia due to diverse molecular mechanisms , 2019, Nature Communications.

[7]  K. Strauch,et al.  Sorafenib As Maintenance Therapy Post Allogeneic Stem Cell Transplantation for FLT3-ITD Positive AML: Results from the Randomized, Double-Blind, Placebo-Controlled Multicentre Sormain Trial , 2018, Blood.

[8]  E. Estey,et al.  Quizartinib, an FLT3 inhibitor, as monotherapy in patients with relapsed or refractory acute myeloid leukaemia: an open-label, multicentre, single-arm, phase 2 trial. , 2018, The Lancet. Oncology.

[9]  M. Caligiuri,et al.  Sorafenib promotes graft-versus-leukemia activity in mice and humans through IL-15 production in FLT3-ITD-mutant leukemia cells , 2018, Nature Medicine.

[10]  A. Olshen,et al.  Heterogeneous resistance to quizartinib in acute myeloid leukemia revealed by single-cell analysis. , 2017, Blood.

[11]  C. Bloomfield,et al.  Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation , 2017, The New England journal of medicine.

[12]  R. Larson,et al.  Selective Inhibition of FLT3 by Gilteritinib in Relapsed/Refractory Acute Myeloid Leukemia: a Multicenter, First-in-human, Open-label, Phase 1/2 Study , 2017, The Lancet. Oncology.

[13]  Haiching Ma,et al.  Comprehensive kinase profile of pacritinib, a nonmyelosuppressive Janus kinase 2 inhibitor , 2016, Journal of experimental pharmacology.

[14]  W. Hiddemann,et al.  Spectrum and prognostic relevance of driver gene mutations in acute myeloid leukemia. , 2016, Blood.

[15]  R. Collins,et al.  Crenolanib besylate, a type I pan-FLT3 inhibitor, to demonstrate clinical activity in multiply relapsed FLT3-ITD and D835 AML. , 2016 .

[16]  H. Einsele,et al.  Addition of sorafenib versus placebo to standard therapy in patients aged 60 years or younger with newly diagnosed acute myeloid leukaemia (SORAML): a multicentre, phase 2, randomised controlled trial. , 2015, The Lancet. Oncology.

[17]  M. McCarthy,et al.  Age-related clonal hematopoiesis associated with adverse outcomes. , 2014, The New England journal of medicine.

[18]  S. Aerts,et al.  JAK3 mutants transform hematopoietic cells through JAK1 activation, causing T-cell acute lymphoblastic leukemia in a mouse model. , 2014, Blood.

[19]  S. Gabriel,et al.  Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence. , 2014, The New England journal of medicine.

[20]  J. Hansford,et al.  A unique case of refractory primary mediastinal B-cell lymphoma with JAK3 mutation and the role for targeted therapy , 2014, Haematologica.

[21]  R. Jove,et al.  Role of altered growth factor receptor-mediated JAK2 signaling in growth and maintenance of human acute myeloid leukemia stem cells. , 2014, Blood.

[22]  P. Gaulard,et al.  JAK3 deregulation by activating mutations confers invasive growth advantage in extranodal nasal-type natural killer cell lymphoma , 2014, Leukemia.

[23]  M. Stern,et al.  Recurrent JAK1 and JAK3 somatic mutations in T-cell prolymphocytic leukemia , 2014, Leukemia.

[24]  A. Krämer,et al.  Sorafenib in combination with intensive chemotherapy in elderly patients with acute myeloid leukemia: results from a randomized, placebo-controlled trial. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  N. Gray,et al.  Using combination therapy to override stromal-mediated chemoresistance in mutant FLT3-positive AML: synergism between FLT3 inhibitors, dasatinib/multi-targeted inhibitors and JAK inhibitors , 2012, Leukemia.

[26]  M. Heinrich,et al.  Newly described activating JAK3 mutations in T-cell acute lymphoblastic leukemia , 2012, Leukemia.

[27]  W. Sellers,et al.  Modulation of activation-loop phosphorylation by JAK inhibitors is binding mode dependent. , 2012, Cancer discovery.

[28]  Andrew Kasarskis,et al.  Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukaemia , 2012, Nature.

[29]  Kiran C. Bobba,et al.  The genetic basis of early T-cell precursor acute lymphoblastic leukaemia , 2012, Nature.

[30]  M. Furihata,et al.  Expression of p‐JAK2 predicts clinical outcome and is a potential molecular target of acute myelogenous leukemia , 2011, International journal of cancer.

[31]  A. Poulsen,et al.  SB1518, a novel macrocyclic pyrimidine-based JAK2 inhibitor for the treatment of myeloid and lymphoid malignancies , 2011, Leukemia.

[32]  T. Ikezoe,et al.  Inhibition of signal transducer and activator of transcription 5 by the inhibitor of janus kinases stimulates dormant human leukemia CD34+/CD38− cells and sensitizes them to antileukemia agents , 2011, International journal of cancer.

[33]  I. Behrmann,et al.  Jak1 has a dominant role over Jak3 in signal transduction through γc-containing cytokine receptors. , 2011, Chemistry & biology.

[34]  M. Konopleva,et al.  Phase I study of sorafenib in patients with refractory or relapsed acute leukemias , 2011, Haematologica.

[35]  C. Peschel,et al.  Identification of a secondary FLT3/A848P mutation in a patient with FLT3-ITD-positive blast phase CMML and response to sunitinib and sorafenib , 2010, Leukemia.

[36]  J. Downing,et al.  Rearrangement of CRLF2 is associated with mutation of JAK kinases, alteration of IKZF1, Hispanic/Latino ethnicity, and a poor outcome in pediatric B-progenitor acute lymphoblastic leukemia. , 2010, Blood.

[37]  H. Kantarjian,et al.  Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms. , 2010, Blood.

[38]  M. Loh,et al.  JAK mutations in high-risk childhood acute lymphoblastic leukemia , 2009, Proceedings of the National Academy of Sciences.

[39]  B. Druker,et al.  RNAi screen for rapid therapeutic target identification in leukemia patients , 2009, Proceedings of the National Academy of Sciences.

[40]  R. Engh,et al.  FMS-like tyrosine kinase 3-internal tandem duplication tyrosine kinase inhibitors display a nonoverlapping profile of resistance mutations in vitro. , 2009, Cancer research.

[41]  A. Baruchel,et al.  Activating mutations in human acute megakaryoblastic leukemia. , 2008, Blood.

[42]  Y. Chung,et al.  Somatic Mutations of JAK1 and JAK3 in Acute Leukemias and Solid Cancers , 2008, Clinical Cancer Research.

[43]  H. Fujii.  Receptor expression is essential for proliferation induced by dimerized Jak kinases. , 2008, Biochemical and biophysical research communications.

[44]  U. Mony,et al.  Resistance to FLT3 inhibition in an in vitro model of primary AML cells with a stem cell phenotype in a defined microenvironment , 2008, Leukemia.

[45]  Axel Benner,et al.  Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia. , 2008, The New England journal of medicine.

[46]  R. Wilson,et al.  Identification of somatic JAK1 mutations in patients with acute myeloid leukemia. , 2008, Blood.

[47]  E. Clappier,et al.  Somatically acquired JAK1 mutations in adult acute lymphoblastic leukemia , 2008, The Journal of experimental medicine.

[48]  K. Glaser,et al.  Enhanced activation of STAT pathways and overexpression of survivin confer resistance to FLT3 inhibitors and could be therapeutic targets in AML. , 2007, Blood.

[49]  T. Naoe,et al.  JAK3 mutations occur in acute megakaryoblastic leukemia both in Down syndrome children and non-Down syndrome adults , 2007, Leukemia.

[50]  K. Mills,et al.  The effects of lestaurtinib (CEP701) and PKC412 on primary AML blasts: the induction of cytotoxicity varies with dependence on FLT3 signaling in both FLT3-mutated and wild-type cases. , 2006, Blood.

[51]  E. Estey,et al.  Plasma inhibitory activity (PIA): a pharmacodynamic assay reveals insights into the basis for cytotoxic response to FLT3 inhibitors. , 2006, Blood.

[52]  Sandra A. Moore,et al.  Activating alleles of JAK3 in acute megakaryoblastic leukemia. , 2006, Cancer cell.

[53]  Mario Cazzola,et al.  A gain-of-function mutation of JAK2 in myeloproliferative disorders. , 2005, The New England journal of medicine.

[54]  Randy Allred,et al.  A phase 1 study of SU11248 in the treatment of patients with refractory or resistant acute myeloid leukemia (AML) or not amenable to conventional therapy for the disease. , 2005, Blood.

[55]  R. Clark,et al.  A phase 2 trial of the FLT3 inhibitor lestaurtinib (CEP701) as first-line treatment for older patients with acute myeloid leukemia not considered fit for intensive chemotherapy. , 2004 .

[56]  W. Berdel,et al.  Flt3 mutations from patients with acute myeloid leukemia induce transformation of 32D cells mediated by the Ras and STAT5 pathways. , 2000, Blood.

[57]  G. Stark,et al.  Jak1 plays an essential role for receptor phosphorylation and Stat activation in response to granulocyte colony-stimulating factor. , 1997, Blood.

[58]  J. Wang,et al.  Src homology 2 domain as a specificity determinant in the c-Abl-mediated tyrosine phosphorylation of the RNA polymerase II carboxyl-terminal repeated domain. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[59]  R. Stone,et al.  Clinical resistance to the kinase inhibitor PKC412 in acute myeloid leukemia by mutation of Asn-676 in the FLT3 tyrosine kinase domain. , 2006, Blood.

[60]  E. Estey,et al.  Patients with acute myeloid leukemia and an activating mutation in FLT3 respond to a small-molecule FLT3 tyrosine kinase inhibitor, PKC412 , 2004 .

[61]  G. Ehninger,et al.  Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis. , 2002, Blood.